<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702010</url>
  </required_header>
  <id_info>
    <org_study_id>EST-MED-2018-01</org_study_id>
    <secondary_id>E.C.P.S. 18/1398</secondary_id>
    <nct_id>NCT03702010</nct_id>
  </id_info>
  <brief_title>Spinal Cord Stimulation in Patients With Post-Laminectomy Syndrome in Testing Phase</brief_title>
  <official_title>Randomized, Single-blind, Multicenter, Crossover, Controlled Clinical Trial to Compare Difference on the Visual Analogue Scale With Two Modes of Spinal Cord Stimulation in Patients With Post-Laminectomy Syndrome in Testing Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally, pain relief through spinal cord stimulation has been associated with the&#xD;
      appearance of paresthesia in the affected area. Several parameters are set to maximize the&#xD;
      overexposure zone, such as frequency,and pulse width. Although this technique has improved&#xD;
      pain in many patients, paresthesia itself can be uncomfortable. Traditionally, the occurrence&#xD;
      of paresthesias has been considered to be a predictor of success in pain elimination, while&#xD;
      the non-occurrence of paresthesias would indicate failure. So far, few studies have reported&#xD;
      pain relief below the threshold of onset of paresthesia. Some clinical trials for pathologies&#xD;
      other than the one considered in this study have achieved relief below the threshold by&#xD;
      reducing the amplitude of the stimulus. Recently, however, it has been observed in a pilot&#xD;
      study that, by increasing the frequency of spinal cord stimulation to 1 kilohertz, it is&#xD;
      possible to significantly improve pain relief compared to less frequent conventional&#xD;
      stimulation based on the occurrence of paresthesias.&#xD;
&#xD;
      A recent review by the Cochrane Library concluded that conventional spinal cord stimulation&#xD;
      for pain relief of Failed Back Surgery Syndrome (or FBSS) requires further clinical studies&#xD;
      and better designs to demonstrate its superiority over other therapeutic options. Therefore,&#xD;
      although spinal cord stimulation is accepted by the Food and Drug Administration (FDA) and&#xD;
      the European Medicines Agency (EMA), new techniques are being introduced that offer better&#xD;
      results in terms of pain relief. Among these techniques, there is the high frequency mode,&#xD;
      which allows avoiding the annoying sensation of paresthesia that substitutes pain with the&#xD;
      conventional technique. In order to provide greater rigour and scientific quality, the&#xD;
      present study is proposed, in which the conventional spinal cord stimulation (CME) technique&#xD;
      (control branch or CME) is compared with paresthesias and a standard frequency (60 hertz)&#xD;
      with a high frequency (1000 hertz) EVOLVE system (Evolve workflow - standardized guidance to&#xD;
      simplify the trial and implant experience and optimize patient outcomes) (experimental branch&#xD;
      or EME) by means of a design with a high degree of scientific evidence, randomising the&#xD;
      global sample of patients to each of the two branches of stimulation in the study (blind to&#xD;
      the patient) and crossing the branches after a period of washing&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-blind, multicenter, crossover</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline, After first stimulation (5days), after washout and second stimulation (12 days), After 30-day follow-up (42 days)</time_frame>
    <description>Visual analogue scale (VAS) at the end of each test phase (either with conventional spinal cord stimulation or with EVOLVE). VAS consists of a 10 centimeter (cm) line, whose ends are defined as the extreme limits of pain (left end corresponds with the absence of pain and the right end with the maximum amount of pain).&#xD;
The patient is asked to point out in the line the place that better correspond to his/her pain, ranging from 0 to 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change (%) in VAS Scale at the End of Treatment.</measure>
    <time_frame>After first stimulation (Five days after baseline), After second stimulation (12 days after baseline), at the end of follow-up (42 days after baseline)</time_frame>
    <description>Change (%) in Visual Analogue Scale (VAS) at the end of treatment.&#xD;
Δ = [(VAS Initial Visit - VAS Final Visit) / VAS initial visit] *100&#xD;
Please note that positive values indicate a decrease in the VAS scale, which would indicate pain relief, as it was calculated as the value at the earlier time point minus the value at the later time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation Disability</measure>
    <time_frame>Baseline, After first stimulation (+5 days), After washout and second stimulation (+12 days), at the end of follow-up (+42days)</time_frame>
    <description>Oswestry Disability Index of the patients: it is a questionnaire consisting of 10 questions with 6 possible answers each. Every answer gives a punctuation from 0 (less disability) to 5 (more disability).&#xD;
This scale is expressed in percentage in which 0 percentage (%) would the least disability and 100 percentage (%) would represent the maximum disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events in Each Arm</measure>
    <time_frame>42 days from baseline</time_frame>
    <description>Considering as an adverse event those that result in death, or in severe harm to patient's health (lesion that threatens life, permanent harm on an organ or corporal function, or process that needs a medical or surgical intervention to avoid permanent harm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Laminectomy</condition>
  <condition>Post-laminectomy Syndrome</condition>
  <condition>Spinal Cord Syndrome</condition>
  <condition>Failed Back Surgery Syndrome</condition>
  <arm_group>
    <arm_group_label>CME branch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this study, the conventional spinal cord stimulation method (control Branch-CME branch)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EME branch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>spinal cord stimulation conventional</intervention_name>
    <description>If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.</description>
    <arm_group_label>CME branch</arm_group_label>
    <other_name>CME</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>spinal cord stimulation experimental</intervention_name>
    <description>If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.</description>
    <arm_group_label>EME branch</arm_group_label>
    <other_name>EME</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
          -  Patients with FBSS syndrome with leg pain or leg and back pain.&#xD;
&#xD;
          -  Get a score on the visual analogue scale (VAS) ≥ 7.&#xD;
&#xD;
          -  Have received medical pharmacological treatment for at least 6 months after back&#xD;
             surgery.&#xD;
&#xD;
          -  The patient has signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age.&#xD;
&#xD;
          -  Patients who require a diathermic energy source (microwave, ultrasound or short wave).&#xD;
&#xD;
          -  Patients with a pacemaker.&#xD;
&#xD;
          -  Patients carrying a defibrillator.&#xD;
&#xD;
          -  Patient with a cochlear implant.&#xD;
&#xD;
          -  Patients with other active implanted devices.&#xD;
&#xD;
          -  Patients who are scheduled to have any of the following procedures during the study&#xD;
             period: an MRI, defibrillation or cardioversion, electrocautery, lithotripsy,&#xD;
             radiofrequency or microwave ablation, and any other high-frequency ultrasound&#xD;
             procedure,&#xD;
&#xD;
          -  Women of childbearing age who do not use adequate contraception.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Participation in another trial.&#xD;
&#xD;
          -  Patients who have expressed a desire not to participate in the study and have not&#xD;
             formed informed consent.&#xD;
&#xD;
          -  Patients with a failed spinal cord stimulation implant previously&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Sánchez-Montero, MD</last_name>
    <role>Study Director</role>
    <affiliation>IBSAL-Instituto de Investigación Biomédica de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Pedro de Logroño</name>
      <address>
        <city>Logroño</city>
        <state>La Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <results_first_submitted>April 12, 2021</results_first_submitted>
  <results_first_submitted_qc>August 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2021</results_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal cord stimulation</keyword>
  <keyword>Back surgery</keyword>
  <keyword>Chronic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Failed Back Surgery Syndrome</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03702010/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03702010/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Planned enrollment: 24. Final enrollment: 27. Screened: 28.</recruitment_details>
      <pre_assignment_details>27 of 28 patients screened were randomized, as one patient did not meet inclusion/exclusion criteria.&#xD;
All patients underwent both treatments, as the study design was cross-section.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CME - EME Branch</title>
          <description>In this study, the conventional spinal cord stimulation method (control Branch-CME branch)&#xD;
CME control group: after mapping the search for the pain area, the neurostimulator is programmed to conventional stimulation with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.&#xD;
The device is then deprogrammed and a 2-day washout period is initiated.&#xD;
On day 7, EME protocol is initiated: stimulation is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days.</description>
        </group>
        <group group_id="P2">
          <title>EME - CME Branch</title>
          <description>In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)&#xD;
EME experimental group: fter mapping the search for the pain area, the neurostimulator is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days.&#xD;
The device is then deprogrammed and a 2-day washout period is initiated.&#xD;
On day 7, conventional CME stimulation is programmed with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Stimulation (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout + Second Stimulation (2+5days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up (30days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants underwent both neurostimulation protocols, as it was a crossover study.</population>
      <group_list>
        <group group_id="B1">
          <title>CME - EME Branch</title>
          <description>After mapping the search for the pain area, the neurostimulator is programmed to conventional stimulation (CME) with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.&#xD;
The device is then deprogrammed and a 2-day washout period is initiated.&#xD;
On day 7, EME experimental protocol is initiated: stimulation is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>EME - CME Branch</title>
          <description>After mapping the search for the pain area, the neurostimulator is programmed to EME experimental protocol is initiated: stimulation is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days.&#xD;
The device is then deprogrammed and a 2-day washout period is initiated.&#xD;
On day 7, conventional stimulation (CME) stimulation is programmed with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="13.1"/>
                    <measurement group_id="B2" value="53.9" spread="12.6"/>
                    <measurement group_id="B3" value="52.4" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="4.3"/>
                    <measurement group_id="B2" value="28.2" spread="4.3"/>
                    <measurement group_id="B3" value="27.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparing Visual Analogue Scale (VAS)</title>
        <description>Visual analogue scale (VAS) at the end of each test phase (either with conventional spinal cord stimulation or with EVOLVE). VAS consists of a 10 centimeter (cm) line, whose ends are defined as the extreme limits of pain (left end corresponds with the absence of pain and the right end with the maximum amount of pain).&#xD;
The patient is asked to point out in the line the place that better correspond to his/her pain, ranging from 0 to 10.</description>
        <time_frame>Baseline, After first stimulation (5days), after washout and second stimulation (12 days), After 30-day follow-up (42 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CME -EME Branch</title>
            <description>Conventional CME: after mapping the search for the pain area, the neurostimulator is programmed to conventional stimulation with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.&#xD;
The device is then deprogrammed and a 2-day washout period is initiated.&#xD;
On day 7, EME protocol is initiated: stimulation is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>EME-CME Branch</title>
            <description>EVOLVE programming guide (EME): after mapping the search for the pain area, the neurostimulator is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days&#xD;
The device is then deprogrammed and a 2-day washout period is initiated.&#xD;
On day 7, CME protocol is initiated: stimulation is programmed to conventional stimulation with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Visual Analogue Scale (VAS)</title>
          <description>Visual analogue scale (VAS) at the end of each test phase (either with conventional spinal cord stimulation or with EVOLVE). VAS consists of a 10 centimeter (cm) line, whose ends are defined as the extreme limits of pain (left end corresponds with the absence of pain and the right end with the maximum amount of pain).&#xD;
The patient is asked to point out in the line the place that better correspond to his/her pain, ranging from 0 to 10.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="1.1"/>
                    <measurement group_id="O2" value="8.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After first stimulation (day +5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="1.7"/>
                    <measurement group_id="O2" value="4.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After washout and second stimulation (day +12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.2"/>
                    <measurement group_id="O2" value="5.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Follow-up (day +42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.8"/>
                    <measurement group_id="O2" value="4.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline VAS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.112</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After first stimulation VAS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After second stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.760</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of Follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.624</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change (%) in VAS Scale at the End of Treatment.</title>
        <description>Change (%) in Visual Analogue Scale (VAS) at the end of treatment.&#xD;
Δ = [(VAS Initial Visit - VAS Final Visit) / VAS initial visit] *100&#xD;
Please note that positive values indicate a decrease in the VAS scale, which would indicate pain relief, as it was calculated as the value at the earlier time point minus the value at the later time point.</description>
        <time_frame>After first stimulation (Five days after baseline), After second stimulation (12 days after baseline), at the end of follow-up (42 days after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CME - EME Branch</title>
            <description>Conventional spinal cord stimulation (CME) method for 5 days. Washout of 2 days. Experimental spinal cord stimulation (EME) for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>EME - CME Branch</title>
            <description>Experimental spinal cord stimulation (EME) method for 5 days. Washout of 2 days. Conventional spinal cord stimulation (CME) for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change (%) in VAS Scale at the End of Treatment.</title>
          <description>Change (%) in Visual Analogue Scale (VAS) at the end of treatment.&#xD;
Δ = [(VAS Initial Visit - VAS Final Visit) / VAS initial visit] *100&#xD;
Please note that positive values indicate a decrease in the VAS scale, which would indicate pain relief, as it was calculated as the value at the earlier time point minus the value at the later time point.</description>
          <units>percentage of VAS change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="26.0"/>
                    <measurement group_id="O2" value="37.4" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After second stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="29.1"/>
                    <measurement group_id="O2" value="41.5" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="28.1"/>
                    <measurement group_id="O2" value="48.8" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After first stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.589</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After second stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.704</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of Follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.908</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation Disability</title>
        <description>Oswestry Disability Index of the patients: it is a questionnaire consisting of 10 questions with 6 possible answers each. Every answer gives a punctuation from 0 (less disability) to 5 (more disability).&#xD;
This scale is expressed in percentage in which 0 percentage (%) would the least disability and 100 percentage (%) would represent the maximum disability.</description>
        <time_frame>Baseline, After first stimulation (+5 days), After washout and second stimulation (+12 days), at the end of follow-up (+42days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CME - EME Branch</title>
            <description>CME conventional stimulation for 5 days, Washout for 2 days. EME evolve experimental stimulation for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>EME - CME Branch</title>
            <description>EVOLVE programming guide (EME) experimental stimulation for 5 days. Washout for 2 days. Conventional stimulation (CME) for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation Disability</title>
          <description>Oswestry Disability Index of the patients: it is a questionnaire consisting of 10 questions with 6 possible answers each. Every answer gives a punctuation from 0 (less disability) to 5 (more disability).&#xD;
This scale is expressed in percentage in which 0 percentage (%) would the least disability and 100 percentage (%) would represent the maximum disability.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="14.1"/>
                    <measurement group_id="O2" value="65.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After first stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="15.8"/>
                    <measurement group_id="O2" value="41.5" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After second stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="18.7"/>
                    <measurement group_id="O2" value="43.7" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="21.6"/>
                    <measurement group_id="O2" value="24.9" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.231</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After first stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After second stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.998</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of Follow-up</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events in Each Arm</title>
        <description>Considering as an adverse event those that result in death, or in severe harm to patient's health (lesion that threatens life, permanent harm on an organ or corporal function, or process that needs a medical or surgical intervention to avoid permanent harm)</description>
        <time_frame>42 days from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CME - EME</title>
            <description>Conventional stimulation for 5 days Washout for days Experimental stimulation for 5 days</description>
          </group>
          <group group_id="O2">
            <title>EME - CME</title>
            <description>EVOLVE stimulation for 5 days Washout for 2 days Conventional stimulation for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events in Each Arm</title>
          <description>Considering as an adverse event those that result in death, or in severe harm to patient's health (lesion that threatens life, permanent harm on an organ or corporal function, or process that needs a medical or surgical intervention to avoid permanent harm)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to the end of Follow-up (42 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CME - Conventional Stimulation</title>
          <description>Conventional stimulation with paresthesia at 60 Hz and a pulse width between 300-450 μs, for 5 days.</description>
        </group>
        <group group_id="E2">
          <title>EME - EVOLVE Experimental Stimulation</title>
          <description>The neurostimulator is programmed to stimulation is programmed at 90% of the subthreshold with a pulse width of 90 μs and frequency of 1000 Hz, placing the bipole in the T9-T10 space, for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>post-dural puncture headache</sub_title>
                <description>two dural punctures resulting in post-dural puncture headache (one episode on each branch)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>One patient reported pain in the surgical wound, and also experienced abnormal stimulation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Electrode migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abnormal stimulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Francisco José Sánchez Montero</name_or_title>
      <organization>Hospital Universitario de Salamanca</organization>
      <phone>923291100</phone>
      <email>fjsmontero@saludcastillayleon.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

